{"entity":"pfizer","id":"ent_pfizer","name":"Pfizer","wikidata":"Q206921","page":"https://asof.is/record/pfizer","summary":"Pfizer is an American multinational pharmaceutical and biotechnology corporation, headquartered in New York. It reported revenue of $62.58B for the period ended December 31, 2025.","title":"Pfizer: revenue $62.58B","key_facts":[{"label":"Chair","value":"Albert Bourla","claim":"clm_97BD9CF6DBEF"},{"label":"Headquarters","value":"New York","claim":"clm_9F456988276D"},{"label":"Revenue","value":"$62.58B","recorded":"62,579,000,000 United States dollar","note":"to 2025-12-31","claim":"clm_55A653F47AF3"},{"label":"Ticker","value":"PFE · NYSE","claim":"clm_7E1A04BD9171"}],"faq":[{"question":"Where is Pfizer headquartered?","answer":"New York."},{"question":"What is Pfizer's revenue?","answer":"$62.58B for the period ended December 31, 2025."}],"as_of":"2026-11-10","known_by":null,"since":null,"fact_pages":[{"predicate":"chair","page":"https://asof.is/record/pfizer/chair","md":"https://asof.is/record/pfizer/chair.md","json":"https://asof.is/v1/entities/pfizer/chair"},{"predicate":"headquarters","page":"https://asof.is/record/pfizer/headquarters","md":"https://asof.is/record/pfizer/headquarters.md","json":"https://asof.is/v1/entities/pfizer/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/pfizer/revenue","md":"https://asof.is/record/pfizer/revenue.md","json":"https://asof.is/v1/entities/pfizer/revenue"},{"predicate":"net_income","page":"https://asof.is/record/pfizer/net_income","md":"https://asof.is/record/pfizer/net_income.md","json":"https://asof.is/v1/entities/pfizer/net_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/pfizer/quarterly_revenue","md":"https://asof.is/record/pfizer/quarterly_revenue.md","json":"https://asof.is/v1/entities/pfizer/quarterly_revenue"}],"products":[],"coverage":{"entity":"pfizer","name":"Pfizer","kind":"organization","sources":[{"source":"wikidata","item":"Q206921","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":78003,"ticker":"PFE","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":439,"open":17,"retracted":0,"first":"1994-03-18","predicates":{"quarterly_net_income":{"claims":56,"open":1,"kind":"fact"},"shares_outstanding":{"claims":70,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":48,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":76,"open":1,"kind":"fact"},"total_equity":{"claims":73,"open":1,"kind":"fact"},"revenue":{"claims":17,"open":1,"kind":"fact"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"total_assets":{"claims":71,"open":1,"kind":"fact"},"net_income":{"claims":19,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"chair":{"claims":1,"open":1,"kind":"fact"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":439,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_23E72D4D980E","predicate":"cash_and_equivalents","value":"1,824,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,824,000,000 United States dollar\", as of 2026-09-27. Claim clm_23E72D4D980E, https://asof.is/claim/clm_23E72D4D980E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_23E72D4D980E","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_97BD9CF6DBEF","predicate":"chair","value":"Albert Bourla","valid_from":"2020-01-01","valid_to":null,"published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer chair: Albert Bourla\", as of 2020-01-01. Claim clm_97BD9CF6DBEF, https://asof.is/claim/clm_97BD9CF6DBEF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm.","url":"https://asof.is/claim/clm_97BD9CF6DBEF","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm","tier":"primary","publisher":"SEC EDGAR 10-K","published_at":"2026-02-26T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Albert Bourla, DVM, Ph.D. 64 Chairman of the Board since January 2020 and Chief Executive Officer since January 2019.","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm"}},{"id":"clm_A432390F07DC","predicate":"cik","value":"0000078003","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cik: 0000078003\", undated. Claim clm_A432390F07DC, https://asof.is/claim/clm_A432390F07DC, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003.","url":"https://asof.is/claim/clm_A432390F07DC","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_C0E8CD376AF8","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer fiscal year end: 12-31\", undated. Claim clm_C0E8CD376AF8, https://asof.is/claim/clm_C0E8CD376AF8, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003.","url":"https://asof.is/claim/clm_C0E8CD376AF8","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_9F456988276D","predicate":"headquarters","value":"New York","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer headquarters: New York\", undated. Claim clm_9F456988276D, https://asof.is/claim/clm_9F456988276D, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003.","url":"https://asof.is/claim/clm_9F456988276D","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_0BE50E5F9477","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer listed on: NYSE\", undated. Claim clm_0BE50E5F9477, https://asof.is/claim/clm_0BE50E5F9477, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003.","url":"https://asof.is/claim/clm_0BE50E5F9477","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B68A9D81D6E4","predicate":"net_income","value":"7,771,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 7,771,000,000 United States dollar\", as of 2025-12-31. Claim clm_B68A9D81D6E4, https://asof.is/claim/clm_B68A9D81D6E4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_B68A9D81D6E4","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-26"}},{"id":"clm_7B5F356BDB2E","predicate":"quarterly_net_income","value":"3,242,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,242,000,000 United States dollar\", as of 2026-09-27. Claim clm_7B5F356BDB2E, https://asof.is/claim/clm_7B5F356BDB2E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_7B5F356BDB2E","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_F01F5C40574B","predicate":"quarterly_revenue","value":"16,583,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 16,583,000,000 United States dollar\", as of 2026-09-27. Claim clm_F01F5C40574B, https://asof.is/claim/clm_F01F5C40574B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_F01F5C40574B","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_CEBC4E588547","predicate":"registrant_name","value":"PFIZER INC","valid_from":"1994-03-18","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer registrant name: PFIZER INC\", as of 1994-03-18. Claim clm_CEBC4E588547, https://asof.is/claim/clm_CEBC4E588547, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003.","url":"https://asof.is/claim/clm_CEBC4E588547","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_55A653F47AF3","predicate":"revenue","value":"62,579,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 62,579,000,000 United States dollar\", as of 2025-12-31. Claim clm_55A653F47AF3, https://asof.is/claim/clm_55A653F47AF3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_55A653F47AF3","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2025, filed 2026-02-26"}},{"id":"clm_7F37B9735E29","predicate":"shares_outstanding","value":"5,699,853,733 shares","valid_from":"2026-10-28","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,699,853,733 shares\", as of 2026-10-28. Claim clm_7F37B9735E29, https://asof.is/claim/clm_7F37B9735E29, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_7F37B9735E29","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_268C36420A0C","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_268C36420A0C, https://asof.is/claim/clm_268C36420A0C, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003.","url":"https://asof.is/claim/clm_268C36420A0C","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_CA83172AAB24","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer state of incorporation: DE\", undated. Claim clm_CA83172AAB24, https://asof.is/claim/clm_CA83172AAB24, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003.","url":"https://asof.is/claim/clm_CA83172AAB24","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7E1A04BD9171","predicate":"ticker","value":"PFE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer ticker: PFE\", undated. Claim clm_7E1A04BD9171, https://asof.is/claim/clm_7E1A04BD9171, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003.","url":"https://asof.is/claim/clm_7E1A04BD9171","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_E3BBF3297E77","predicate":"total_assets","value":"204,544,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 204,544,000,000 United States dollar\", as of 2026-09-27. Claim clm_E3BBF3297E77, https://asof.is/claim/clm_E3BBF3297E77, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_E3BBF3297E77","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_84ED4CDADE9C","predicate":"total_equity","value":"89,001,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 89,001,000,000 United States dollar\", as of 2026-09-27. Claim clm_84ED4CDADE9C, https://asof.is/claim/clm_84ED4CDADE9C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_84ED4CDADE9C","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-03"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date"}}}